Beta-blockers in heart failure prognosis: Lessons learned by MECKI Score Group papers.

Cattadori G; Di Marco S; Farina S; Limongelli G; Monda E; Badagliacca R; Papa S; Tricarico L; Correale M;

European journal of preventive cardiology [Eur J Prev Cardiol] 2020 Dec; Vol. 27 (2_suppl), pp. 65-71.

Heart failure is a complex syndrome affecting several organs including kidney, lungs, liver, brain muscles and sympathetic system. Each of these organs might contribute to its severity and prognosis. The prognosis assessment is critical for a correct heart failure management. It has already been demonstrated that a single parameter is weaker for prognosis than different parameters combined. The Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score has been built and validated for heart failure with reduced ejection fraction (HFrEF) patients by considering cardiopulmonary exercise test data combined with clinical, laboratory and echocardiographic measurements. The betablockers treatment is a milestone in the HFrEF management. In the MECKI score database, the association of betablockers treatment with outcome has been investigated in different settings.